capecitabine has been researched along with Bile Duct Cancer in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (22.50) | 29.6817 |
| 2010's | 19 (47.50) | 24.3611 |
| 2020's | 12 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, M; Li, Y; Wang, Z; Yang, Y; Yuan, Z; Zeng, T; Zhang, D; Zhou, W | 1 |
| Budhu, A; Duffy, AG; Figg, WD; Greten, TF; Kleiner, DE; Ma, L; Mabry, D; Monge, C; Pehrsson, EC; Redd, B; Steinberg, SM; Tandon, M; Wang, S; Wei Wang, X; Wood, BJ; Xie, C | 1 |
| Boudjema, K; Bourien, H; Campillo-Gimenez, B; Edeline, J; Garin, E; Rolland, Y; Trochet, M | 1 |
| Abadi, S; Davies, JM; Ho, C; Mathers, B; McIntyre, C | 1 |
| Li, XH; Lin, XJ; Zhao, CY; Zhou, EL | 1 |
| Ahmed, O; Baker, T; Fung, J; Hwang, G; Liao, CY; Patel, M; Pillai, A; Yu, Q | 1 |
| Bath, NM; Pawlik, TM | 1 |
| Chon, HJ; Hwang, DW; Jeong, H; Jeong, JH; Kim, KH; Kim, KP; Lee, JH; Lee, JS; Lee, MA; Moon, DB; Park, JH; Park, SJ; Ryoo, BY; Yoo, C | 1 |
| Gu, HF; Hu, YF; Jin, YW; Li, FY | 1 |
| Jeong, H; Yoo, C | 1 |
| Aprile, G; Brandi, G; Brieau, B; Casadei-Gardini, A; Dahan, L; Evesque, L; Filippi, R; Le Sourd, S; Lièvre, A; Lonardi, S; Meurisse, A; Neuzillet, C; Pointet, AL; Rousseau, B; Scartozzi, M; Silvestris, N; Tougeron, D; Vernerey, D; Vienot, A; Vivaldi, C | 1 |
| Benoit, C; Biau, J; Lapeyre, M; Moreau, J; Pezet, D | 1 |
| Baiu, I; Charville, GW; Visser, BC | 1 |
| Brezault, C; Coriat, R; Guillaumot, MA; Léandri, C; Ribiere, SC | 1 |
| Case, R; Myrick, S; Stoner, P; Zimmermann, E | 1 |
| Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B | 1 |
| Chindaprasirt, J; Khuntikeo, N; Ngamprasertchai, T; Pakkhem, A; Sookprasert, A; Ungarereevittaya, P; Wirasorn, K | 1 |
| Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU | 1 |
| Kim, BH; Kim, CM; Kim, TH; Kim, YI; Koh, YH; Lee, WJ; Park, JW; Woo, SM | 1 |
| Alberts, SR; Gores, GJ; Haddock, MG; Heimbach, JK; Martenson, JA; Miller, RC; Novotny, PJ; Rosen, CB; Sio, TT | 1 |
| Hoegdall, DT; Jensen, LH; Larsen, FO; Mellergaard, AH | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM | 1 |
| Grande, C; Groman, A; Iancu, DM; Iyer, RV; Ma, WW; Malhotra, U; Pokuri, VK; Saab, TB | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Marrero, JA; Singal, A; Welling, TH | 1 |
| Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J | 1 |
| Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z | 1 |
| Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R | 1 |
| Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C | 1 |
| Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM | 1 |
| Alexandrescu, S; Becheanu, G; Buica, F; Croitoru, A; Diculescu, M; Dinu, I; Gheorghe, L; Gramaticu, I; Herlea, V; Hrehoret, D; Luca, I; Lupescu, I; Popescu, I; Simionov, I | 1 |
| Knox, JJ; Zhu, AX | 1 |
| Ahn, JH; Chang, HM; Kang, HJ; Kang, YK; Kim, JH; Kim, TW; Lee, JR; Lee, JS; Ryu, MH | 1 |
| Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA | 1 |
| Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H | 1 |
| Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA | 1 |
| Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N | 1 |
| Heinemann, V; Schalhorn, A; Stemmler, J | 1 |
7 review(s) available for capecitabine and Bile Duct Cancer
| Article | Year |
|---|---|
PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cholangiocarcinoma; Humans; Immune Checkpoint Inhibitors; Maintenance Chemotherapy; Male; Middle Aged | 2021 |
Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Humans | 2023 |
[Intra and extra hepatic cholangiocarcinomas radiation therapy].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cholangiocarcinoma; Humans; Prognosis; Radiosurgery; Radiotherapy, Adjuvant | 2021 |
[Therapeutic advances in the management of biliary tract carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; France; Gemcitabine; Humans; Medical Oncology | 2018 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Role of liver transplantation in the treatment of cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Liver Transplantation; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Risk Factors; Survival Rate; Treatment Outcome | 2009 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
13 trial(s) available for capecitabine and Bile Duct Cancer
| Article | Year |
|---|---|
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract; Capecitabine; Carcinoma; Gastrointestinal Neoplasms; Humans; Oxaliplatin | 2022 |
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2015 |
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2018 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leukopenia; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase | 2011 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
20 other study(ies) available for capecitabine and Bile Duct Cancer
| Article | Year |
|---|---|
Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined with Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHOlangiocarcinoma: The SIROCHO Trial Design.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Humans; Radiopharmaceuticals | 2023 |
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Fluorouracil; Humans; Retrospective Studies; Treatment Outcome | 2023 |
Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Humans; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2022 |
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Cisplatin; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2023 |
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Female; Fluorouracil; France; Humans; Irinotecan; Italy; Male; Middle Aged; Platinum; Prospective Studies; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
When Lightning Strikes Twice.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Second Primary; Pancreaticoduodenectomy; Reoperation; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Solitary ascending colon ulcer diagnosed as gastrointestinal CMV disease.
Topics: Adult; Antimetabolites, Antineoplastic; Antiviral Agents; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colitis; Colon, Ascending; Cytomegalovirus Infections; Female; Gastrointestinal Hemorrhage; Humans; Immunocompromised Host; Pancreaticoduodenectomy; Risk Factors; Ulcer; Valacyclovir | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fluorouracil; Humans; Inguinal Canal; Leucovorin; Liver; Liver Neoplasms; Lymphatic Metastasis; Male; Microsatellite Instability; Neoplasm, Residual; Nivolumab; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Treatment Outcome | 2019 |
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2013 |
Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Diagnostic Techniques, Surgical; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate | 2016 |
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Severity of Illness Index | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; CA-19-9 Antigen; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; CA-125 Antigen; Capecitabine; Carcinoembryonic Antigen; Carrier Proteins; CDX2 Transcription Factor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cytokines; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Glycoproteins; Hepatectomy; Homeodomain Proteins; Humans; Immunohistochemistry; Keratin-20; Keratins; Liver; Liver Neoplasms; Lymph Node Excision; Magnetic Resonance Imaging; Membrane Transport Proteins; Phenotype; Portal Vein; Pregnancy; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Multivariate Analysis; Probability; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment | 2002 |